Kanya Rajangam - Aug 5, 2021 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role: Chief Medical Officer
Signature: /s/ Alicia Hager, as Attorney-in-Fact
Stock symbol: NKTX
Transactions as of: Aug 5, 2021
Transactions value $: -$368,700
Form type: 4
Date filed: 8/9/2021, 05:17 PM
Next filing: Jan 19, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NKTX	Common Stock	Options Exercise	$4.1K	+10K		$0.41^*	10K	Aug 5, 2021	Direct	F1
transaction	NKTX	Common Stock	Sale	-$373K	-10K	-100%	$37.28^*	0	Aug 5, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NKTX	Stock Option (right to buy)	Options Exercise	$0	-10K	-18.5%	$0.00	44.1K	Aug 5, 2021	Common Stock	10K	$0.41	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date.
F2	This transaction was executed in multiple trades at prices ranging from $37.02 to $37.63, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on December 3, 2022.